ProQR Therapeutics NV
(NAS:PRQR)
$
1.665
-0.035 (-2.06%)
Market Cap: 135.97 Mil
Enterprise Value: 46.30 Mil
PE Ratio: 0
PB Ratio: 3.60
GF Score: 47/100 - ProQR Therapeutics NV R&D Day TranscriptMar 29, 2023
- ProQR Therapeutics NV Lilly Partnership Expansion and Axiomer Overview TranscriptDec 22, 2022
- ProQR Therapeutics NV Management Call TranscriptAug 11, 2022
- ProQR Therapeutics NV Additional Sepofarsen Analyses and Company Strategy Update Call TranscriptApr 13, 2022
- ProQR Therapeutics NV Top-Line Results Phase 2/3 Illuminate Trial - Corporate Call TranscriptFeb 11, 2022
- ProQR Therapeutics NV Analyst Event TranscriptNov 18, 2021
- ProQR Therapeutics NV at Chardan Genetic Medicines Conference (Virtual) TranscriptOct 05, 2021
- ProQR Therapeutics NV at Citi BioPharma Conference (Virtual) TranscriptSep 09, 2021
- ProQR Therapeutics NV Axiomer RNA Call TranscriptSep 09, 2021
- ProQR Therapeutics NV Review of Phase 1/2 Stellar Data in Usher/nsRP Hosted By Cantor Fitzgerald TranscriptMar 25, 2021
- ProQR Therapeutics NV to Discuss the Results of Phase 1/2 Stellar trial of QR-421a in Adults with Usher Syndrome and nSRP TranscriptMar 24, 2021
- ProQR Therapeutics NV at H C Wainwright Global Life Sciences Conference (Virtual) TranscriptMar 09, 2021
- ProQR Therapeutics NV Expert Perspectives Call TranscriptFeb 22, 2021
- Apellis Pharmaceuticals Inc, Aerie Pharmaceuticals, Aldeyra Therapeutics, and ProQR Therapeutic at Citi BioPharma Conference (Virtual) - Panel TranscriptSep 10, 2020
- ProQR Therapeutics NV Expert Perspectives Series -- LCA10 and Sepofarsen - Call TranscriptJul 20, 2020
- ProQR Therapeutics NV Expert Perspectives Series -- Usher Syndrome and Retinitis Pigmentosa - Call TranscriptJun 22, 2020
ProQR Therapeutics NV Review of Phase 1/2 Stellar Data in Usher/nsRP Hosted By Cantor Fitzgerald Transcript
Release Date Price:
$9.22
(+62.32%)
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent ![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust_rating.png)
4.6 out of 5
Trustpilot
![](https://static.gurufocus.com/trust.png)